Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Harvard Apparatus Regenerative Technology, Inc.BSTG · Entity 7501 | Director | March 14, 2018 | March 28, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Harvard Apparatus Regenerative Technology, Inc.
Report date March 14, 2018 · Filed March 28, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 3,412 |
Reported balance
After 2018-03-14 transaction · row 1
1 source rowRow 1 · 2018-03-14 · Exercise / conversion · Acquired 912 · Balance 3,412 F1: Each restricted stock unit was the economic equivalent of one share of the Issuer's common stock. The reporting person settled the vested restricted stock units for shares of the Issuer's common stock. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2018-03-14 | Direct | 0 |
Reported balance
After 2018-03-14 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2018-03-14 · Exercise / conversion · Disposed 912 · Balance 0 F1: Each restricted stock unit was the economic equivalent of one share of the Issuer's common stock. The reporting person settled the vested restricted stock units for shares of the Issuer's common stock. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit was the economic equivalent of one share of the Issuer's common stock. The reporting person settled the vested restricted stock units for shares of the Issuer's common stock.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
CYNOSURE INC
Report date March 22, 2017 · Filed March 24, 2017
Section 16 reporting ended · disclosed 2017-03-24. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2017-03-22 transaction · row 1
1 source rowRow 1 · 2017-03-22 · Other · Disposed 14,514 · Balance 0 F1: Pursuant to the terms of that certain Agreement and Plan of Merger, dated as of February 14, 2017, by and among Hologic, Inc., Minuteman Merger Sub, Inc. and Cynosure, Inc. (the "Merger Agreement"), these shares were tendered and disposed of at the Acceptance Time (all terms capitalized but not defined shall have the meaning given to them in the Merger Agreement) in exchange for the right to receive $66.00 per share, net to the seller in cash, without interest, less any required withholding taxes (the "Merger Consideration"). |
| Stock Option (right to purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $30.74 · Expires 2017-05-16 | Direct | 0 |
Reported balance
After 2017-03-22 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2017-03-22 · Disposition to issuer · Disposed 2,500 · Balance 0 F2: This stock option was fully vested and exercisable prior to the Effective Time. Pursuant to the terms of the Merger Agreement, each outstanding and unexercised stock option as of immediately prior to the Effective Time, whether vested or unvested, was automatically canceled and converted into the right to receive, for each underlying share, the difference between the Merger Consideration and the exercise price per share of the option. |
| Stock Option (right to purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $35.00 · Expires 2017-11-05 | Direct | 0 |
Reported balance
After 2017-03-22 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2017-03-22 · Disposition to issuer · Disposed 5,000 · Balance 0 F2: This stock option was fully vested and exercisable prior to the Effective Time. Pursuant to the terms of the Merger Agreement, each outstanding and unexercised stock option as of immediately prior to the Effective Time, whether vested or unvested, was automatically canceled and converted into the right to receive, for each underlying share, the difference between the Merger Consideration and the exercise price per share of the option. |
| Stock Option (right to purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $23.45 · Expires 2023-06-24 | Direct | 0 |
Reported balance
After 2017-03-22 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2017-03-22 · Disposition to issuer · Disposed 8,000 · Balance 0 F2: This stock option was fully vested and exercisable prior to the Effective Time. Pursuant to the terms of the Merger Agreement, each outstanding and unexercised stock option as of immediately prior to the Effective Time, whether vested or unvested, was automatically canceled and converted into the right to receive, for each underlying share, the difference between the Merger Consideration and the exercise price per share of the option. |
| Stock Option (right to purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $21.11 · Expires 2024-05-14 | Direct | 0 |
Reported balance
After 2017-03-22 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2017-03-22 · Disposition to issuer · Disposed 10,648 · Balance 0 F2: This stock option was fully vested and exercisable prior to the Effective Time. Pursuant to the terms of the Merger Agreement, each outstanding and unexercised stock option as of immediately prior to the Effective Time, whether vested or unvested, was automatically canceled and converted into the right to receive, for each underlying share, the difference between the Merger Consideration and the exercise price per share of the option. |
| Stock Option (right to purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $35.37 · Expires 2025-05-14 | Direct | 0 |
Reported balance
After 2017-03-22 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2017-03-22 · Disposition to issuer · Disposed 5,244 · Balance 0 F2: This stock option was fully vested and exercisable prior to the Effective Time. Pursuant to the terms of the Merger Agreement, each outstanding and unexercised stock option as of immediately prior to the Effective Time, whether vested or unvested, was automatically canceled and converted into the right to receive, for each underlying share, the difference between the Merger Consideration and the exercise price per share of the option. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Expires 2026-05-11 | Direct | 0 |
Reported balance
After 2017-03-22 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2017-03-22 · Disposition to issuer · Disposed 1,272 · Balance 0 F3: Each restricted stock unit represents a contingent right to receive one share of Cynosure, Inc.'s common stock. F4: Pursuant to the terms of the Merger Agreement, each outstanding and unvested restricted stock unit as of immediately prior to the Effective Time vested in full and was automatically canceled and converted into the right to receive the Merger Consideration for each underlying share. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the terms of that certain Agreement and Plan of Merger, dated as of February 14, 2017, by and among Hologic, Inc., Minuteman Merger Sub, Inc. and Cynosure, Inc. (the "Merger Agreement"), these shares were tendered and disposed of at the Acceptance Time (all terms capitalized but not defined shall have the meaning given to them in the Merger Agreement) in exchange for the right to receive $66.00 per share, net to the seller in cash, without interest, less any required withholding taxes (the "Merger Consideration").
F2: This stock option was fully vested and exercisable prior to the Effective Time. Pursuant to the terms of the Merger Agreement, each outstanding and unexercised stock option as of immediately prior to the Effective Time, whether vested or unvested, was automatically canceled and converted into the right to receive, for each underlying share, the difference between the Merger Consideration and the exercise price per share of the option.
F3: Each restricted stock unit represents a contingent right to receive one share of Cynosure, Inc.'s common stock.
F4: Pursuant to the terms of the Merger Agreement, each outstanding and unvested restricted stock unit as of immediately prior to the Effective Time vested in full and was automatically canceled and converted into the right to receive the Merger Consideration for each underlying share.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 14, 2018 Filed Mar 28, 2018 17:11 UTC | Harvard Apparatus Regenerative Technology, Inc. BSTG · Entity 7501 | Exercise / conversionRestricted Stock Units · Derivative | 912 | Not disclosed Strike: $0.00 | Not disclosed |
DisclosureSEC source: 0001144204-18-017597 · tv489776_form4.xml · derivative · entry 2 Robinson Thomas H · CIK 0001345855 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 912 shares Expires 2018-03-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit was the economic equivalent of one share of the Issuer's common stock. The reporting person settled the vested restricted stock units for shares of the Issuer's common stock. Read SEC document |
| March 14, 2018 Filed Mar 28, 2018 17:11 UTC | Harvard Apparatus Regenerative Technology, Inc. BSTG · Entity 7501 | Exercise / conversionCommon Stock | 912 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001144204-18-017597 · tv489776_form4.xml · nonDerivative · entry 1 Robinson Thomas H · CIK 0001345855 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,412 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit was the economic equivalent of one share of the Issuer's common stock. The reporting person settled the vested restricted stock units for shares of the Issuer's common stock. Read SEC document |
| March 22, 2017 Filed Mar 24, 2017 16:48 UTC | CYNOSURE INC CYNO · Entity 177540 | Disposition to issuerRestricted Stock Units · Derivative | 1,272 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-17-008534 · doc4.xml · derivative · entry 7 Robinson Thomas H · CIK 0001345855 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 1,272 shares Expires 2026-05-11 F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Cynosure, Inc.'s common stock. F4 · price: Pursuant to the terms of the Merger Agreement, each outstanding and unvested restricted stock unit as of immediately prior to the Effective Time vested in full and was automatically canceled and converted into the right to receive the Merger Consideration for each underlying share. F4 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, each outstanding and unvested restricted stock unit as of immediately prior to the Effective Time vested in full and was automatically canceled and converted into the right to receive the Merger Consideration for each underlying share. Read SEC document |
| March 22, 2017 Filed Mar 24, 2017 16:48 UTC | CYNOSURE INC CYNO · Entity 177540 | Disposition to issuerStock Option (right to purchase) · Derivative | 5,244 | Not disclosed Strike: $35.37 | Not disclosed |
DisclosureSEC source: 0000899243-17-008534 · doc4.xml · derivative · entry 6 Robinson Thomas H · CIK 0001345855 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 5,244 shares Expires 2025-05-14 F2 · price: This stock option was fully vested and exercisable prior to the Effective Time. Pursuant to the terms of the Merger Agreement, each outstanding and unexercised stock option as of immediately prior to the Effective Time, whether vested or unvested, was automatically canceled and converted into the right to receive, for each underlying share, the difference between the Merger Consideration and the exercise price per share of the option. F2 · derivative.exercise_date: This stock option was fully vested and exercisable prior to the Effective Time. Pursuant to the terms of the Merger Agreement, each outstanding and unexercised stock option as of immediately prior to the Effective Time, whether vested or unvested, was automatically canceled and converted into the right to receive, for each underlying share, the difference between the Merger Consideration and the exercise price per share of the option. Read SEC document |
| March 22, 2017 Filed Mar 24, 2017 16:48 UTC | CYNOSURE INC CYNO · Entity 177540 | Disposition to issuerStock Option (right to purchase) · Derivative | 10,648 | Not disclosed Strike: $21.11 | Not disclosed |
DisclosureSEC source: 0000899243-17-008534 · doc4.xml · derivative · entry 5 Robinson Thomas H · CIK 0001345855 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 10,648 shares Expires 2024-05-14 F2 · price: This stock option was fully vested and exercisable prior to the Effective Time. Pursuant to the terms of the Merger Agreement, each outstanding and unexercised stock option as of immediately prior to the Effective Time, whether vested or unvested, was automatically canceled and converted into the right to receive, for each underlying share, the difference between the Merger Consideration and the exercise price per share of the option. F2 · derivative.exercise_date: This stock option was fully vested and exercisable prior to the Effective Time. Pursuant to the terms of the Merger Agreement, each outstanding and unexercised stock option as of immediately prior to the Effective Time, whether vested or unvested, was automatically canceled and converted into the right to receive, for each underlying share, the difference between the Merger Consideration and the exercise price per share of the option. Read SEC document |
| March 22, 2017 Filed Mar 24, 2017 16:48 UTC | CYNOSURE INC CYNO · Entity 177540 | Disposition to issuerStock Option (right to purchase) · Derivative | 8,000 | Not disclosed Strike: $23.45 | Not disclosed |
DisclosureSEC source: 0000899243-17-008534 · doc4.xml · derivative · entry 4 Robinson Thomas H · CIK 0001345855 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 8,000 shares Expires 2023-06-24 F2 · price: This stock option was fully vested and exercisable prior to the Effective Time. Pursuant to the terms of the Merger Agreement, each outstanding and unexercised stock option as of immediately prior to the Effective Time, whether vested or unvested, was automatically canceled and converted into the right to receive, for each underlying share, the difference between the Merger Consideration and the exercise price per share of the option. F2 · derivative.exercise_date: This stock option was fully vested and exercisable prior to the Effective Time. Pursuant to the terms of the Merger Agreement, each outstanding and unexercised stock option as of immediately prior to the Effective Time, whether vested or unvested, was automatically canceled and converted into the right to receive, for each underlying share, the difference between the Merger Consideration and the exercise price per share of the option. Read SEC document |
| March 22, 2017 Filed Mar 24, 2017 16:48 UTC | CYNOSURE INC CYNO · Entity 177540 | Disposition to issuerStock Option (right to purchase) · Derivative | 5,000 | Not disclosed Strike: $35.00 | Not disclosed |
DisclosureSEC source: 0000899243-17-008534 · doc4.xml · derivative · entry 3 Robinson Thomas H · CIK 0001345855 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 5,000 shares Expires 2017-11-05 F2 · price: This stock option was fully vested and exercisable prior to the Effective Time. Pursuant to the terms of the Merger Agreement, each outstanding and unexercised stock option as of immediately prior to the Effective Time, whether vested or unvested, was automatically canceled and converted into the right to receive, for each underlying share, the difference between the Merger Consideration and the exercise price per share of the option. F2 · derivative.exercise_date: This stock option was fully vested and exercisable prior to the Effective Time. Pursuant to the terms of the Merger Agreement, each outstanding and unexercised stock option as of immediately prior to the Effective Time, whether vested or unvested, was automatically canceled and converted into the right to receive, for each underlying share, the difference between the Merger Consideration and the exercise price per share of the option. Read SEC document |
| March 22, 2017 Filed Mar 24, 2017 16:48 UTC | CYNOSURE INC CYNO · Entity 177540 | Disposition to issuerStock Option (right to purchase) · Derivative | 2,500 | Not disclosed Strike: $30.74 | Not disclosed |
DisclosureSEC source: 0000899243-17-008534 · doc4.xml · derivative · entry 2 Robinson Thomas H · CIK 0001345855 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 2,500 shares Expires 2017-05-16 F2 · price: This stock option was fully vested and exercisable prior to the Effective Time. Pursuant to the terms of the Merger Agreement, each outstanding and unexercised stock option as of immediately prior to the Effective Time, whether vested or unvested, was automatically canceled and converted into the right to receive, for each underlying share, the difference between the Merger Consideration and the exercise price per share of the option. F2 · derivative.exercise_date: This stock option was fully vested and exercisable prior to the Effective Time. Pursuant to the terms of the Merger Agreement, each outstanding and unexercised stock option as of immediately prior to the Effective Time, whether vested or unvested, was automatically canceled and converted into the right to receive, for each underlying share, the difference between the Merger Consideration and the exercise price per share of the option. Read SEC document |
| March 22, 2017 Filed Mar 24, 2017 16:48 UTC | CYNOSURE INC CYNO · Entity 177540 | OtherClass A Common Stock | 14,514 | $66.00 | $957,924.00 |
DisclosureSEC source: 0000899243-17-008534 · doc4.xml · nonDerivative · entry 1 Robinson Thomas H · CIK 0001345855 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · shares: Pursuant to the terms of that certain Agreement and Plan of Merger, dated as of February 14, 2017, by and among Hologic, Inc., Minuteman Merger Sub, Inc. and Cynosure, Inc. (the "Merger Agreement"), these shares were tendered and disposed of at the Acceptance Time (all terms capitalized but not defined shall have the meaning given to them in the Merger Agreement) in exchange for the right to receive $66.00 per share, net to the seller in cash, without interest, less any required withholding taxes (the "Merger Consideration"). Read SEC document |
| March 14, 2017 Filed Mar 16, 2017 16:21 UTC | Harvard Apparatus Regenerative Technology, Inc. BSTG · Entity 7501 | GrantRestricted Stock Units · Derivative | 18,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-17-015103 · v461958_4.xml · derivative · entry 2 Robinson Thomas H · CIK 0001345855 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,250 Underlying: Common Stock, par value $0.01 per share · 18,250 shares Expires not disclosed F2 · derivative.exercise_price: Restricted stock units granted by the Issuer pursuant to its 2013 Equity Incentive Plan and qualified under Rule 16b-3(d). Each restricted stock unit represents a contingent right to receive one share of Common Stock of the Issuer. F3 · derivative.exercise_date: The restricted stock units vest and settle in full one year from the date of grant. F3 · derivative.expiration_date: The restricted stock units vest and settle in full one year from the date of grant. Read SEC document |
| March 14, 2017 Filed Mar 16, 2017 16:21 UTC | Harvard Apparatus Regenerative Technology, Inc. BSTG · Entity 7501 | GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $0.38 | $0.00 |
DisclosureSEC source: 0001144204-17-015103 · v461958_4.xml · derivative · entry 1 Robinson Thomas H · CIK 0001345855 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock, par value $0.01 per share · 25,000 shares Expires 2027-03-14 F1 · derivative.exercise_date: The option shares vest in full one year from the date of grant. Read SEC document |
| February 11, 2017 Filed Feb 14, 2017 17:58 UTC | CYNOSURE INC CYNO · Entity 177540 | Exercise / conversionRestricted Stock Units · Derivative | 1,271 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-010729 · doc4.xml · derivative · entry 2 Robinson Thomas H · CIK 0001345855 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,271 Underlying: Class A Common Stock · 1,271 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of the issuer's Class A common stock upon vesting of the unit. F3 · derivative.exercise_date: The restricted stock units vest as to approximately 25% of the shares on each three-month anniversary of the grant date of May 11, 2016. F3 · derivative.expiration_date: The restricted stock units vest as to approximately 25% of the shares on each three-month anniversary of the grant date of May 11, 2016. Read SEC document |
| February 11, 2017 Filed Feb 14, 2017 17:58 UTC | CYNOSURE INC CYNO · Entity 177540 | Exercise / conversionClass A Common Stock | 1,271 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-010729 · doc4.xml · nonDerivative · entry 1 Robinson Thomas H · CIK 0001345855 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,514 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: On February 11, 2017, 1,271 shares that were acquired by the reporting person pursuant to the award of restricted stock units on May 11, 2016 vested and were paid to the reporting person. Read SEC document |
| November 11, 2016 Filed Nov 15, 2016 13:51 UTC | CYNOSURE INC CYNO · Entity 177540 | Exercise / conversionRestricted Stock Units · Derivative | 1,271 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-16-150083 · doc4.xml · derivative · entry 2 Robinson Thomas H · CIK 0001345855 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,543 Underlying: Class A Common Stock · 1,271 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of the issuer's Class A common stock upon vesting of the unit. F3 · derivative.exercise_date: The restricted stock units vest as to approximately 25% of the shares on each three-month anniversary of the grant date of May 11, 2016. F3 · derivative.expiration_date: The restricted stock units vest as to approximately 25% of the shares on each three-month anniversary of the grant date of May 11, 2016. Read SEC document |
| November 11, 2016 Filed Nov 15, 2016 13:51 UTC | CYNOSURE INC CYNO · Entity 177540 | Exercise / conversionClass A Common Stock | 1,271 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-16-150083 · doc4.xml · nonDerivative · entry 1 Robinson Thomas H · CIK 0001345855 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,243 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: On November 11, 2016, 1,271 shares that were acquired by the reporting person pursuant to the award of restricted stock units on May 11, 2016 vested and were paid to the reporting person. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.